FENC
NASDAQFennec Pharmaceuticals Inc.
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
Price$6.98+0.37 (+5.60%)
01:45 PM07:00 PM
News · 26 weeks68-15%
2025-10-262026-04-19
Mix3290d
- Insider15(47%)
- SEC Filings8(25%)
- Other6(19%)
- Earnings2(6%)
- Analyst1(3%)
Latest news
25 items- SECFennec Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - FENNEC PHARMACEUTICALS INC. (0001211583) (Filer)
- PRFennec Pharmaceuticals Announces Acceptance of Abstracts at the 2026 ASCO Annual Meeting– Data from Four Studies Spotlight Rising Clinical Interest & Urgency to Address Cisplatin-Induced Hearing Loss and Its Lasting Impact on Patients – RESEARCH TRIANGLE PARK, N.C., April 21, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a specialty pharmaceutical company, today announced that four abstracts evaluating PEDMARK® (sodium thiosulfate injection) were accepted as part of the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting program, taking place May 29-June 2, 2026 in Chicago, IL. PEDMARK® is currently approved for pediatric patients one month of age and older with localized, non-metastatic solid tumors, and is also recognized by the
- SECFennec Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - FENNEC PHARMACEUTICALS INC. (0001211583) (Filer)
- PRFennec Pharmaceuticals Announces Investigator-Sponsored Study to Be Conducted by University of Arizona Cancer Center~ University of Arizona Cancer Center Initiating Study to Explore Use of PEDMARK® in AYA & Adult Patients with Solid Tumors Receiving Cisplatin ~ ~ This New Study and Other Independent, Institution-Led Research Continues to Expand Real-World Validation of PEDMARK® Across New Tumor Types and Patient Populations ~ RESEARCH TRIANGLE PARK, N.C., April 07, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a specialty pharmaceutical company, today announced the initiation of an investigator-sponsored study by University of Arizona Cancer Center to evaluate use of PEDMARK® (sodium thiosulfate injection) in adolescent and young adult (AYA) and adult patients with hea
- INSIDERSEC Form 4 filed by Cioffi Christiana Marie4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
- INSIDERSEC Form 4 filed by Hackman Jeffrey S.4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
- INSIDERSEC Form 4 filed by Raykov Rosty4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
- INSIDERSEC Form 4 filed by Sayad Pierre Sargis4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
- INSIDERSEC Form 4 filed by Evans Terry L4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
- INSIDERSEC Form 4 filed by Andrade Robert4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
- PRFennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)RESEARCH TRIANGLE PARK, N.C., March 31, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) ("Fennec" or the "Company"), a specialty pharmaceutical company, today announced that on March 17, 2026, the Compensation Committee of the Company's Board of Directors approved the grant of incentive stock option awards ("ISOs") to purchase an aggregate of 377,500 of the Company's common shares to 24 new non-executive employees of the Company with a grant date of March 31, 2026 under the Company's 2026 Equity Inducement Plan (the "Inducement Plan"). The ISOs were granted as inducements material to the employees entering into employment with the Company in accordance with Nas
- SECSEC Form 10-K filed by Fennec Pharmaceuticals Inc.10-K - FENNEC PHARMACEUTICALS INC. (0001211583) (Filer)
- INSIDERSEC Form 4 filed by Andrade Robert4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
- INSIDERSEC Form 4 filed by Cioffi Christiana Marie4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
- SECFennec Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - FENNEC PHARMACEUTICALS INC. (0001211583) (Filer)
- PRFennec Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update~ Delivered Record Annual Revenue with Full-Year Net PEDMARK® Product Sales of $44.6 Million, Representing 50% Year-Over-Year Growth, and Q4 2025 Net Product Sales of $13.8 Million, Representing 75% Growth Over Q4 2024 Net Product Sales ~ ~ Executed on 2025 Clinical Data Strategy to Expand Real-World Validation of PEDMARK® Across New Tumor Types and Patient Populations Through Independent, Institution-Led Research ~ ~ Achieved Record Performance with All-Time High Patient Enrollments and Conversion Rates in Q4 2025, Reflecting Strong Field Execution ~ ~ Completed Oversubscribed $42 Million Equity Offerings with Participation from New and Existing Investors ~ ~ Announced Positive Toplin
- PRFennec Pharmaceuticals to Report Full Year and Fourth Quarter 2025 Financial Results on March 24, 2026RESEARCH TRIANGLE PARK, N.C., March 18, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its full year and fourth quarter 2025 financial results before the opening of the U.S. financial markets on Tuesday, March 24, 2026. Management will host a conference call and webcast that day to discuss the Company's financial and business results. Conference Call & Webcast Detail: Date: Tuesday, March 24, 2026Time: 8:30 a.m. Eastern TimeWebcast Link: https://edge.media-server.com/mmc/p/3crq898eParticipant Link: https://register-conf.media-server.com/register/BIb7d9f04377fd4
- SECFennec Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - FENNEC PHARMACEUTICALS INC. (0001211583) (Filer)
- PRFennec Pharmaceuticals Announces Settlement Agreement Resolving PEDMARK Patent LitigationRESEARCH TRIANGLE PARK, N.C., March 16, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a specialty pharmaceutical company, today announces that it has entered into an agreement with Cipla Limited and Cipla USA, Inc. to settle the litigation between them regarding Cipla's application to FDA for approval to market a generic version of Fennec's PEDMARK® (sodium thiosulfate injection) product. See Fennec Pharmaceuticals Inc. v. Cipla Limited and Cipla USA, Inc., C.A. No. 2:23-cv-00123-JKS-MAH (D.N.J.). Under the terms of the agreement, the lawsuit will be dismissed with each party bearing their own costs, and Cipla will not enter the market with its generic sodium
- SECSEC Form S-8 filed by Fennec Pharmaceuticals Inc.S-8 - FENNEC PHARMACEUTICALS INC. (0001211583) (Filer)
- SECFennec Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - FENNEC PHARMACEUTICALS INC. (0001211583) (Filer)
- PRFennec Pharmaceuticals Announces Clinical Research Collaboration with Tampa General Hospital Cancer InstituteRESEARCH TRIANGLE PARK, N.C., March 04, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a specialty pharmaceutical company, today announced that the Tampa General Hospital (TGH) Cancer Institute is initiating a study evaluating the real-world clinical utility of sodium thiosulfate injection (PEDMARK®) in reducing the risk of ototoxicity in Adolescent and Young Adult (AYA) and adult cancer patients receiving cisplatin-based treatment. "The TGH Cancer Institute, in collaboration with the USF Health Morsani College of Medicine, is committed to better understanding and advancing otoprotective strategies aimed at preserving auditory function in patients receiving c
- INSIDERCHIEF FINANCIAL OFFICER Andrade Robert was granted 1,191 shares, increasing direct ownership by 0.49% to 243,584 units (SEC Form 4)4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
- INSIDERDirector Raykov Rosty exercised 15,598 shares at a strike of $2.45, sold $84,260 worth of shares (10,079 units at $8.36) and was granted 5,208 shares, increasing direct ownership by 11% to 109,204 units (SEC Form 4)4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
- SECFennec Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - FENNEC PHARMACEUTICALS INC. (0001211583) (Filer)